There are currently 51 active clinical trials seeking participants for Glioma research studies. The states with the highest number of trials for Glioma participants are California, Pennsylvania, Ohio and Michigan.
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/11/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +37 locations
Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
Register for Updates
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
NCT05937776
Recruiting
This is an observational study to compare the utility of the novel aMRI approach in human brain to the standard of care imaging approach for diagnosing and assessing glioma. Tumor cells have altered metabolism compared to normal cells.This makes metabolic activity imaging useful for diagnosing and assessing neurological disease. However, current options for metabolic activity imaging are limited. Metabolic activity imaging is primarily conducted using positron emission tomography (PET) with a ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Glioma
Register for Updates
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
NCT01772771
Recruiting
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.
Gender:
ALL
Ages:
All
Trial Updated:
03/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Sarcoma, Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma
Register for Updates
Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients
NCT05511324
Recruiting
Family caregivers of patients with a primary brain tumor experience a high caregiving load including assistance with activities of daily living without any formal training. It is not surprising that this vulnerable caregiver population reports high levels of distress along with numerous caregiving-related concerns, which may compromise their ability to provide quality care. This project will examine the feasibility and initial evidence for efficacy of a caregiving skills intervention aiming to i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Glioma
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +156 locations
Conditions: H3 K27M, Glioma
Register for Updates
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706
Recruiting
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
02/26/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +52 locations
Conditions: Glioma
Register for Updates
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
NCT06855628
Recruiting
The goal of this study is to evaluate the prognostic capacity of DMI in a trial assessing the efficacy of adding BPM31510, a lipid nano dispersion of CoQ10 to standard treatment of Glioblastoma (GBM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Stanford University, Palo Alto, California
Conditions: Glioma, GBM
Register for Updates
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
NCT05773326
Recruiting
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
Register for Updates
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
NCT05555550
Recruiting
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2025
Locations: The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant, Glioma Intracranial
Register for Updates
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT06344130
Recruiting
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy. Objective: To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiati... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Astrocytoma, Glioma, Recurrent Glioblastoma
Register for Updates
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
NCT04186832
Recruiting
This trial studies the feasibility of monitoring step count as a measure of physical activity in patients with newly diagnosed glioma undergoing radiation therapy. Physical activity measured by step count may help to improve the quality of life and symptoms for patients with newly diagnosed glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Glioma, Radiation Therapy Patient
Register for Updates
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
NCT05345002
Recruiting
This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
Register for Updates